Boccara, Franck; Caramelli, Bruno 
; Calmy, Alexandra; Kumar, Princy; Lopez, J. Antonio G.; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S.
Subjects: TERAPIA ANTIRRETROVIRAL DE ALTA ATIVIDADE, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. Aids, v. 36, n. 5, p. 675-682, 2022Tradução . . Disponível em: https://doi.org/10.1097/QAD.0000000000003175. Acesso em: 03 maio 2024.APA
Boccara, F., Caramelli, B., Calmy, A., Kumar, P., Lopez, J. A. G., Bray, S., et al. (2022). Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. Aids, 36( 5), 675-682. doi:10.1097/QAD.0000000000003175NLM
Boccara F, Caramelli B, Calmy A, Kumar P, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period [Internet]. Aids. 2022 ; 36( 5): 675-682.[citado 2024 maio 03 ] Available from: https://doi.org/10.1097/QAD.0000000000003175Vancouver
Boccara F, Caramelli B, Calmy A, Kumar P, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period [Internet]. Aids. 2022 ; 36( 5): 675-682.[citado 2024 maio 03 ] Available from: https://doi.org/10.1097/QAD.0000000000003175
